Update on Follicular Lymphoma – November 16, 2026
Featuring: Dr. John P. Leonard, New York University Langone Health and; Dr. Reid W. Merryman, Dana-Farber Cancer Institute
Category Non-Hodgkin Lymphoma
Elisa Mandato, PhD
Researcher Spotlight: Elisa Mandato, PhD Dana-Farber Cancer Institute Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and the most common hematologic malignancy in the United States. Dr. Mandato’s LRF research project will involve developing…
Researcher Spotlight: Phil Lange, PhD
Dr. Lange is a Postdoctoral Fellow at UNC Lineberger Comprehensive Cancer Center in Chapel Hill, N.C, where he is mentored by Dr. Blossom Damania.
Alexandre Vinaud Hirayama, MD
Researcher Spotlight: Alexandre Vinaud Hirayama, MD Fred Hutchinson Cancer Research Center Chimeric antigen receptor (CAR) T cell therapy is a typeof immunotherapy that genetically modifies a patient’simmune cells to recognize and kill tumor cells. “CAR T cell therapy has shown…
Edmond Feris, PhD
Researcher Spotlight: Edmond Feris, PhD Dartmouth-Hitchcock Norris Cotton Cancer Center Some of the most critical oncogenes responsible fortumor formation in humans are transcription factors. Dr.Feris’ LRF research project focuses on the study of howtranscriptional dysregulation can lead to carcinogenesis(the process…
Elena Battistello, PhD
Researcher Spotlight: Elena Battistello, PhD New York University School of Medicine Peripheral T-cell lymphoma (PTCL) is an aggressive type of non-Hodgkin lymphoma (NHL) derived from the malignant transformation of blood cells called T-lymphocytes. Currently, patients diagnosed with PTCL have limited…
Xu Cao, PhD
Researcher Spotlight: Xu Cao, PhD City of Hope and Beckman Research Institute Many types of non-Hodgkin lymphoma (NHL) remain incurable due to its intrinsic genomic instability facilitating the escape from cytotoxic or targeted therapies. “Recent breakthroughs in understanding macrophage-mediated immune…
Alexia Martinez de Paz, PhD
Researcher Spotlight: Alexia Martinez de Paz, PhD Joan & Sanford I. Weill Medical College of Cornell University Cell-fate transitions (a biological process in which the function of a cell gets specialized, reprogrammed, or altered) during the germinal center (GC) reaction…
Ryan Lynch, MD
Researcher Spotlight: Ryan Lynch, MD University of Washington Checkpoint inhibitors, a type of immunotherapy, have been approved for patients with relapsed Hodgkin lymphoma (HL); however, they do not lead to durable remissions in most patients. Dr. Lynch’s LRF grant project…
Adam Lin, MD, PhD
Researcher Spotlight: Adam Lin, MD, PhD Northwestern University Feinberg School of Medicine Many immunotherapies and cell therapies on the market have increased the cure rate for patients with non-Hodgkin lymphoma (NHL); however, the percentage of relapse and death continues to…